![Shattuck labs](/api/images/company-pic/0-796876-company.png)
Contáctenos
Acerca de la compañía
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.
US
Desconocido
Empresa no verificada
Transparencia empresarial
- No verificó la información de la empresa
- Pide reseñas a sus clientes
- No respondió a las críticas negativas.